Support for shared decision making: "health professionals and patients with early cancer
discuss the risks and benefits of getting additional
therapy ... after surgery".
| developed by |
clinical domains |
keywords |
| Division of Oncology, University of Texas Health Sciences Center, San Antonio |
Cancer care |
Decision support, risk assessment, prognosis |
| commissioned |
status |
Access |
| 2001 |
Available to registered
health professionals. |
Access to Adjuvant! requires pre-registration by a medical professional. The site is not designed for use by patients. |
| description |
|
"Adjuvant! ... had its origins in trying to make information in the San Antonio Data Base more applicable to clinical practice. It draws on information from the SEER data base, the Overviews of clinical trials, individual clinical trial results, and the literature in general" [Adjuvant! FAQ].
"The goal is to help health professionals make estimates of the risk of negative outcome (cancer related mortality or relapse) without systemic adjuvant therapy, estimates of the reduction of these risks afforded by therapy, and risks of side effects of the therapy. These estimates are based on information entered about individual patients and their tumors (for example, patient age, tumor size, nodal involvement, histologic grade, etc.) These estimates are then provided on printed sheets in simple graphical and text formats to be used in consultations.
"Because of the complexity of interpretation of some of the input information (ambiguities about tumor size, margins, etc.), the information should be entered by a health professional with some experience in oncology (cancer medicine).
"
|
| references |
Olivotto IA, Bajdik CD, Ravdin PM at al.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
J Clin Oncol. 2005 Apr 20;23(12):2716-25.
[PubMed]
[]
|
"
PURPOSE: Adjuvant! (www.adjuvantonline.com) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. METHODS: Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer-specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. RESULTS: Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted-observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted-observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. CONCLUSION: Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.
"
|
|
Ravdin PM, Siminoff LA, Davis GJ et al.
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
J Clin Oncol. 2001 Feb 15;19(4):980-91.
[PubMed]
[JCO.ORG]
|
...Actuarial analysis was used to project
outcomes of patients with and without adjuvant
therapy based on estimates of prognosis largely
derived from Surveillance, Epidemiology, and
End-Results data and estimates of the efficacy
of adjuvant therapy based on the 1998 overviews
of randomized trials of adjuvant therapy.
These estimates can be refined using the Prognostic
Factor Impact Calculator, which uses a Bayesian
method to make adjustments based on relative
risks conferred and prevalence of positive
test results... CONCLUSION: The computer program
Adjuvant! can play practical and educational
roles in clinical settings." |
|
Baum M, Ravdin PM.
Decision-making in early breast cancer: guidelines and decision tools.
Eur J Cancer 2002 Apr;38(6):745-9.
[PubMed]
[Elsevier]
|
"This review article explores current guidelines and describes some aids that may be used to help inform women about their treatment options for early breast cancer.
".
The paper includes a description and review of the potential of Adjuvant!
|
|
| contact |
links |
|
Division of Oncology, University of Texas Health Sciences Center, San Antonio.
E: AdjuvantProgram aol.com
|
|
Entry on OpenClinical: May 12 2003
Last main update: May 12 2003, [07 June 2005]
|
|